A systematic review of the clinicopathological features and prognostic outcomes of DICER1-mutant malignant brain neoplasms

Huy Gia Vuong MD, PhD1, Minh-Khang Le MD2, and Ian F. Dunn MD1
View More View Less
  • 1 Department of Neurosurgery, The University of Oklahoma Health Sciences Center, Oklahoma University, Oklahoma City, Oklahoma; and
  • | 2 Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
USD  $45.00
USD  $515.00
USD  $612.00
Print or Print + Online Sign in

OBJECTIVE

DICER1-mutant malignant brain neoplasms are very rare tumors, and published data have relied on case reports or small case series. In this review, the authors aimed to systematically summarize the types and distribution patterns of DICER1 mutations, clinicopathological characteristics, and prognostic outcomes of these tumors.

METHODS

The authors searched PubMed and Web of Science for relevant studies. They included studies if they provided individual patient data of primary malignant brain tumors carrying DICER1 mutations.

RESULTS

The authors found 16 studies consisting of 9 embryonal tumors with multilayered rosettes (ETMRs), 30 pineoblastomas, 52 primary intracranial sarcomas, and 27 pituitary blastomas. Pineoblastoma, ETMR, and pituitary blastoma were more likely to carry DICER1 germline mutations, while only a small subset of primary intracranial sarcomas harbored these mutations (p < 0.001). Nearly 80% of tumors with germline mutations also had another somatic mutation in DICER1. ETMR and primary intracranial sarcoma were associated with an increased risk for tumor progression and relapse compared with pituitary blastoma and pineoblastoma (p = 0.0025), but overall survival (OS) was not significantly different. Gross-total resection (GTR) and radiotherapy administration were associated with prolonged OS.

CONCLUSIONS

ETMR, pineoblastoma, primary intracranial sarcoma, and pituitary blastoma should be considered rare phenotypes of the DICER1 syndrome, and families should be counseled and screened for associated tumors. ETMR and primary intracranial sarcoma had a higher risk of relapse. GTR and radiotherapy appeared to improve the OS of patients with DICER1-mutant malignant intracranial tumors.

ABBREVIATIONS

EOR = extent of resection; ETMR = embryonal tumor with multilayered rosettes; GTR = gross-total resection; OS = overall survival; PFS = progression-free survival; STR = subtotal resection.

Supplementary Materials

    • Figs. S1–S5 and Table S1 (PDF 835 KB)

Illustration from Cinalli et al. (pp 330–341). Printed with permission from © CC Medical Arts.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
USD  $515.00
USD  $612.00
  • 1

    Foulkes WD, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer. 2014;14(10):662672.

  • 2

    Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science. 2009;325(5943):965.

  • 3

    González IA, Stewart DR, Schultz KAP, Field AP, Hill DA, Dehner LP. DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. Mod Pathol. 2022;35(1):422.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    de Kock L, Priest JR, Foulkes WD, Alexandrescu S. An update on the central nervous system manifestations of DICER1 syndrome. Acta Neuropathol. 2020;139(4):689701.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):12311251.

  • 6

    Snuderl M, Kannan K, Pfaff E, et al. Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nat Commun. 2018;9(1):2868.

  • 7

    Lambo S, Gröbner SN, Rausch T, et al. The molecular landscape of ETMR at diagnosis and relapse. Nature. 2019;576(7786):274280.

  • 8

    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Alexandrescu S, Meredith DM, Lidov HG, et al. Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1-mutant. Histopathology. 2021;78(2):265275.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Diaz Coronado RY, Mynarek M, Koelsche C, et al. Primary central nervous system sarcoma with DICER1 mutation–treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer. 2022;128(4):697707.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Koelsche C, Mynarek M, Schrimpf D, et al. Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathol. 2018;136(2):327337.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12

    Liu APY, Kelsey MM, Sabbaghian N, et al. Clinical outcomes and complications of pituitary blastoma. J Clin Endocrinol Metab. 2021;106(2):351363.

  • 13

    Kamihara J, Paulson V, Breen MA, et al. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020;33(10):19101921.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Chong AS, Han H, Albrecht S, Weon YC, Park SK, Foulkes WD. DICER1 syndrome in a young adult with pituitary blastoma. Acta Neuropathol. 2021;142(6):10711076.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15

    Das A, Roy P, Modi SK, et al. Germline DICER1-mutant intracranial sarcoma with dual chondroid and spindle cell morphology and pulmonary metastases treated with multimodal therapy. Pediatr Blood Cancer. 2019;66(7):e27744.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    de Kock L, Sabbaghian N, Druker H, et al. Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol. 2014;128(4):583595.

  • 17

    de Kock L, Sabbaghian N, Plourde F, et al. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol. 2014;128(1):111122.

  • 18

    Lee JC, Mazor T, Lao R, et al. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. Acta Neuropathol. 2019;137(5):851854.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Lee JC, Villanueva-Meyer JE, Ferris SP, et al. Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathol. 2019;137(3):521525.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Li BK, Vasiljevic A, Dufour C, et al. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathol. 2020;139(2):223241.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Sakaguchi M, Nakano Y, Honda-Kitahara M, et al. Two cases of primary supratentorial intracranial rhabdomyosarcoma with DICER1 mutation which may belong to a "spindle cell sarcoma with rhabdomyosarcoma-like feature, DICER1 mutant". Brain Tumor Pathol. 2019;36(4):174182.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    van Engelen K, Villani A, Wasserman JD, et al. DICER1 syndrome: Approach to testing and management at a large pediatric tertiary care center. Pediatr Blood Cancer. 2018;65(1).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23

    Wang L, Lu D, Piao Y. A 2-year-old girl with posterior fossa mass. Brain Pathol. 2022;32(1):e13026.

  • 24

    Castel D, Kergrohen T, Tauziède-Espariat A, et al. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. Acta Neuropathol. 2020;139(6):11091113.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Vuong HG, Le HT, Dunn IF. The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas. Cancer. 2022;128(10):19071912.

  • 26

    Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017;32(4):520537.e5.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Taylor KR, Mackay A, Truffaux N, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014;46(5):457461.

  • 28

    Vuong HG, Ngo TNM, Le HT, et al. Prognostic implication of patient age in H3K27M-mutant midline gliomas. Front Oncol. 2022;12:858148.

  • 29

    Vuong HG, Altibi AMA, Duong UNP, et al. BRAF mutation is associated with an improved survival in glioma—a systematic review and meta-analysis. Mol Neurobiol. 2018;55(5):37183724.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Vuong HG, Le HT, Ngo TNM, et al. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol. 2021;155(3):225234.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31

    Uro-Coste E, Masliah-Planchon J, Siegfried A, et al. ETMR-like infantile cerebellar embryonal tumors in the extended morphologic spectrum of DICER1-related tumors. Acta Neuropathol. 2019;137(1):175177.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    Bahubeshi A, Bal N, Rio Frio T, et al. Germline DICER1 mutations and familial cystic nephroma. J Med Genet. 2010;47(12):863866.

  • 33

    Rio Frio T, Bahubeshi A, Kanellopoulou C, et al. DICER1 mutations in familial multi-nodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA. 2011;305(1):6877.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34

    Paulus W, Kleihues P. Genetic profiling of CNS tumors extends histological classification. Acta Neuropathol. 2010;120(2):269270.

  • 35

    Horwitz M, Dufour C, Leblond P, et al. Embryonal tumors with multilayered rosettes in children: the SFCE experience. Childs Nerv Syst. 2016;32(2):299305.

  • 36

    Scheithauer BW, Kovacs K, Horvath E, et al. Pituitary blastoma. Acta Neuropathol. 2008;116(6):657666.

  • 37

    Kivelä T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17(6):18291837.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38

    de Kock L, Rivera B, Foulkes WD. Pineoblastoma is uniquely tolerant of mutually exclusive loss of DICER1, DROSHA or DGCR8. Acta Neuropathol. 2020;139(6):11151118.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39

    Pfaff E, Aichmüller C, Sill M, et al. Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathol. 2020;139(2):243257.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40

    Graham MS, Mellinghoff IK. Histone-mutant glioma: molecular mechanisms, preclinical models, and implications for therapy. Int J Mol Sci. 2020;21(19):E7193.

  • 41

    Liu APY, Gudenas B, Lin T, et al. Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol. 2020;139(2):259271.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 587 587 131
Full Text Views 72 72 39
PDF Downloads 96 96 57
EPUB Downloads 0 0 0